Premium
The results of liver transplantation with adjuvant chemotherapy for hepatobiliary surgery
Author(s) -
Klintmalm Goran B.,
Stone Marvin J.
Publication year - 1994
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/bf01222237
Subject(s) - medicine , malignancy , chemotherapy , hepatocellular carcinoma , liver transplantation , adjuvant , surgery , doxorubicin , adjuvant chemotherapy , transplantation , gastroenterology , cancer , breast cancer
This is an update of a pilot trial in which doxorubicin 10 mg/m 2 was used pre‐, intra‐, and postoperatively as adjuvant chemotherapy during liver transplant for unresectable hepatocellular carcinoma. The patients had advanced disease, with 17 of 20 having tumors that were multifocal, larger than 5 cm diameter unifocal, or tumors with vascular invasion. Individual followup is now 35–76 months, with a median observation time of 46 months. Eleven of the patients are alive (55%), 2 with recurrences (45% tumor free). Six patients have died from recurrent tumor and 3 from recurrent hepatitis B without evidence of malignancy. Of the eight patients with recurrent tumor, only 1 presented in the grafted liver.